An interventional study of Smart family doctor and Health manager in Hypertension, Diabete Mellitus and Hyperlipidemia, sponsored by China National Center for Cardiovascular Diseases. Not yet recruiting. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-12-18.
Sponsored by China National Center for Cardiovascular Diseases · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Hypertension by China National Center for Cardiovascular Diseases — 8 open to participants now, 9 under way, none of them phase 3. Hypertension · China National Center for Cardiovascular Diseases.
Among the 17 studies in Hypertension by China National Center for Cardiovascular Diseases, this one is the 7th largest by planned enrollment of the 16 interventional ones that give a count, is one of 3 that started in 2026, is one of 13 with no phase, and was the 14th registered.
6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.
Browse Hypertension studies →8 of the 17 studies in Hypertension by China National Center for Cardiovascular Diseases are open now, in 1 country. Recruiting first, the newest first:
China National Center for Cardiovascular Diseases · Sites in China
Ages 18+
China National Center for Cardiovascular Diseases · Sites in China
Ages 18+
China National Center for Cardiovascular Diseases · Sites in China
Ages 20–70
China National Center for Cardiovascular Diseases · Sites in China
Ages 18+
China National Center for Cardiovascular Diseases · Sites in China
Ages 40–70 · Healthy volunteers
By country, each count listing its studies:
Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 951 is above the median of 100 across 4,585 interventional studies indexed under Hypertension.
Median enrollment 480 across the 16 interventional studies, 5,000 across the 1 observational. Of the 4 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
China National Center for Cardiovascular Diseases is the lead sponsor of 271 studies on the registry; 143 are open to participants now.
3 of the studies in Hypertension by China National Center for Cardiovascular Diseases that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06055452China National Center for Cardiovascular DiseasesEffects of SGLT2 Inhibitors in Pre-heart Failure Populations With Hypertension | 2026-12-31 |
| NCT05749874China National Center for Cardiovascular DiseasesEffects of Berberine on Preventing Cardiovascular Disease and Diabetes Mellitus | 2026-12-31 |
| NCT07273513China National Center for Cardiovascular Diseases"Smart Family Doctor" Assisted Comprehensive Management of Secondary Prevention Among Post Revascularization Patients | 2026-12-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 17 studies in Hypertension by China National Center for Cardiovascular Diseases, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to evaluate the effect of an AI-assisted "Smart family doctor" digital health management tool on improving the control rates of hypertension, diabetes, and dyslipidemia in post-revascularization patients. A randomized controlled trial design will be used, involving approximately 10-20 hospitals and 951 participants. Eligible participants are adults aged between 18 and 80 years, post-CABG or post-PCI patients with hypertension, diabetes, and dyslipidemia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
"Smart family doctor", an AI-assisted applications with personalized interactions in 24 hours and 7 days a week.
Behavioral: Smart family doctor
3-hour health management guidance from a health manager once a week.
Behavioral: Health manager
Usual post-surgery management
Behavioral: Usual Care
Participants will be provided "Smart family doctor", which is an AI-assisted applications with personalized interactions. The content includes, but is not limited to: (1) General educational content, covering basic health knowledge on diseases, risk factors, and treatment methods; (2) Targeted health information, such as more specific guidance on blood pressure and blood sugar control, medication adherence, exercise, and smoking cessation; (3) Personalized disease management guidance, providing tailored reminders for patients regarding medication, diet, exercise, and medical visits. Patients can also directly report their latest self-measured blood pressure, blood lipid, blood sugar levels, and medication adherence to receive treatment and medication guidance from the 'Smart family doctor'.
Participants will received 3-hour health management guidance from a health manager once a week, including guidance on healthy lifestyle, medication treatment, and rehabilitation advice.
Participants will receive usual secondary prevention management.
The control rates of hypertension, diabetes and hyperlipidemia
All cretria are meet: 1) Systolic blood pressure less than 130 mmHg and diastolic blood pressure less than 80 mmHg. 2) HbA1c less than 7%. 3) LDL-C less than 1.4 mmol/L.
Time frame: 6-month
Blood Pressure Control Rate
The proportion of patients with systolic blood pressure less than 130 mmHg and diastolic blood pressure less than 80 mmHg.
Time frame: 6-month
Blood glucose Control Rate
The proportion of patients with HbA1c less than 7%.
Time frame: 6-month
Blood lipid Control Rate
The proportion of patients with LDL-C less than 1.4mmol/L.
Time frame: 6-month
Systolic blood pressure
Systolic blood pressure measured at the local site.
Time frame: 6-month
Diastolic blood pressure
Diastolic blood pressure measured at the local site.
Time frame: 6-month
Fasting blood glucose
Fasting blood glucose analyzed at central lab.
Time frame: 6-month
HbA1c
HbA1c analyzed at central lab.
Time frame: 6-month
Total cholesterol
Total cholesterol analyzed at central lab.
Time frame: 6-month
LDL-C
LDL-C analyzed at central lab.
Time frame: 6-month
HDL-C
HDL-C analyzed at central lab.
Time frame: 6-month
Triglycerides
Triglycerides analyzed at central lab.
Time frame: 6-month
Medication adherence (4-item Morisky Medication-Taking Adherence Scale)
Medication adherence measured by MMAS-4. The score range from 0 to 4. The higher score indicated the better medication adherence.
Time frame: 6-month
Coronary artery disease-related quality of life (the Seattle Angina Questionnaire)
Coronary artery disease-related quality of life assessed with the Seattle Angina Questionnaire (SAQ). The score range from 0 to 100. The higher score indicated the better coronary artery disease-related quality of life.
Time frame: 6-month
Smoking Rate
The proportion of patients who have smoked within the past month.
Time frame: 6-month
Major adverse cardiovascular events (MACE)
The composite endpoint of cardiovascular death, myocardial infarction, stroke, or hospitalization due to cardiovascular disease.
Time frame: 6-month
BMI
Body mass index (BMI) is calculated as weights (kg) divided by the square of heights (meters).
Time frame: 6-month
Waist circumference
Waist circumference is measured at local site.
Time frame: 6-month
Rehospitalization rate
The proportion of patients who had hospitalization
Time frame: 6-month
The number of emergency visit
The number of emergency visit during follow-up period
Time frame: 6-month
System usability (system usability scale)
System usability measured by system usability scale. The proportion of patients who scaled system usability more than 68 points.
Time frame: 6-month
Subgroup-age
Primary outcome analyses in age subgroups: \<=65, \>65 years
Time frame: 6-month
Subgroup-sex
Primary outcome analyses in sex subgroups: women, men
Time frame: 6-month
Subgroup-education level
Primary outcome analyses in education level subgroups: less than high school, high school or higher
Time frame: 6-month
Subgroup-smoking status
Primary outcome analyses in smoking status subgroups: current smoking, no smoking
Time frame: 6-month
Subgroup-baseline BP level
Primary outcome analyses in baseline BP level subgroups: SBP/DBP\>=130/80 mmHg, \<130/80 mmHg
Time frame: 6-month
Subgroup-baseline LDL-C level
Primary outcome analyses in baseline LDL-C level subgroups: \<1.4 mmolL, \>=1.4 mmol/L
Time frame: 6-month
Subgroup-baseline HbA1c level
Primary outcome analyses in baseline HbA1c level subgroups: \<7%, \>=7%
Time frame: 6-month
No study locations are listed for this record.
Plan to share: Yes — Anonymized data that support the findings of this study are available from the corresponding author, upon reasonable request, only for authorized research. Their use is subjected to an agreement with the promotor (Fuwai Hospital) and the principal investigator (Dr Xin Yuan) of the SMART II study. Pseudonymised data that support the findings of this study are available from the promotor (Fuwai Hospital) upon reasonable request, subject to a specific agreement with the promotor (involving the principal investigator) and subject to regulatory proceedings due to data protection applicable laws. Access conditions are to be determined depending on the nature of the request.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: At the end of the study
Access criteria: Anonymized data that support the findings of this study are available from the corresponding author, upon reasonable request, only for authorized research. Their use is subjected to an agreement with the promotor (Fuwai Hospital) and the principal investigator (Dr Xin Yuan) of the SMART II study. Pseudonymised data that support the findings of this study are available from the promotor (Fuwai Hospital) upon reasonable request, subject to a specific agreement with the promotor (involving the principal investigator) and subject to regulatory proceedings due to data protection applicable laws. Access conditions are to be determined depending on the nature of the request.
No publications or documents are linked to this record.
Start is estimated for Jan 2026; primary completion for Dec 2026, 11 months later.
Of 1,407 non-industry interventional studies with no phase under Hypertension, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 11 months is below that.
Counting every sponsor, half of 1,502 studies reached it within 23 months; a quarter within 10 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
China National Center for Cardiovascular Diseases →